Dimerix (ASX:DXB) plans to recruit adolescent patients between the ages of 12 and 17, for the ACTION3 clinical trial of its kidney drug DMX-200, the biopharmaceutical company said in a Thursday filing with the Australian bourse.
The patients with focal segmental glomerulosclerosis will be dosed with 120mg of the drug orally and twice daily, the filing said.
Shares of Dimerix fell over 7% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments